Story perspectives

New Intranasal Vaccine Shows Promise Against H5 Influenza

11/7/2025

Summary

Story summary

Researchers at the University of Maryland conducted a Phase I trial of an intranasal adjuvanted H5 influenza vaccine that was well tolerated and primed immune responses.
The vaccine targets diverse H5N1 strains and aims to enhance mucosal immunity in the respiratory tract.
Results indicate potential for broader protection and support pursuing a universal influenza vaccine.
The advancement could improve pandemic preparedness and transform public health responses to influenza outbreaks globally.

1 of 1

Story summary

Researchers at the University of Maryland conducted a Phase I trial of an intranasal adjuvanted H5 influenza vaccine that was well tolerated and primed immune responses.
The vaccine targets diverse H5N1 strains and aims to enhance mucosal immunity in the respiratory tract.
Results indicate potential for broader protection and support pursuing a universal influenza vaccine.
The advancement could improve pandemic preparedness and transform public health responses to influenza outbreaks globally.